Asia-Pacific Anti-Inflammatory Therapeutics Market Expected to Reach $40.5 Billion by 2032

According to a new report published by Allied Market Research, titled, " Asia-Pacific Anti-inflammatory Therapeutics Market by Drug Class, Indication, Distribution Channel, and Country: Global Opportunity Analysis and Industry Forecast, 2023–2032," the Asia-Pacific anti-inflammatory therapeutics market size was valued at $23.8 billion in 2022, and is projected to reach $40.5 billion by 2032, registering a CAGR of 5.4% from 2023 to 2032.

Anti-inflammatory therapeutics are the medications used to reduce inflammation in the body. Inflammation is triggered by the defense system of the body in response to harmful stimuli, damaged cells, irritants and microorganisms. Sometimes, the body’s defense system inappropriately triggers inflammation against its own cells, which results in inflammatory autoimmune diseases. Thus, therapeutics such as non-steroidal anti-inflammatory drugs such as ibuprofen or corticosteroids are used to block the enzymes that produce the anti-inflammatory effect.

In addition, targeted biologics are also used to treat inflammatory diseases with potent activity. These medications manage the wide inflammatory conditions such as lupus, rheumatoid arthritis, or multiple sclerosis.

Factors that drive the growth of Asia-Pacific anti-inflammatory therapeutics market include increase in prevalence of inflammatory diseases, surge in R&D activities for developing novel anti-inflammatory drugs, and expansion of biologics. Increase in the occurrence of chronic inflammatory diseases due to ageing population is the key factor that drives the growth of anti-inflammatory therapeutics market. Aged people are more susceptible to acquire chronic inflammatory diseases such as rheumatoid arthritis.

For instance, Population Reference Bureau (PRB), reported that Japan has the highest old age population with 28% of people aged 65 and above. As the old age population increases, there is a greater demand for inflammatory therapeutics to treat inflammatory diseases, which drives the market growth.

Furthermore, increase in R&D activities for the development of new anti-inflammatory therapeutics to fulfill the unmet medical needs boosts the growth of the market. For instance, Eli Lilly’s Merikizumab is under phase-3 evaluation for the treatment of Crohn’s disease. In addition, ENTYVIO developed by Takeda Pharmaceuticals has completed the clinical evaluation for the treatment of ulcerative colitis. Furthermore, Sanofi S.A. a pharmaceutical company has more than 10 molecules in the clinical evaluation for the treatment of inflammatory diseases. Thus, surge in R&D activities further propels the growth of anti-inflammatory therapeutics market.

In addition, improvement in the regulatory scenario by adoption of regulations such as International Conference on Harmonization (ICH), Good Manufacturing Practice (GMP) guidelines and provisions for both product and process patents also contribute towards the market growth.

However, anti-inflammatory drugs are associated with side effects and complications when used for the long term. The occurrence of side effects limits their use and negatively impacts the market growth. For instance, long term use of NSAIDs such as ibuprofen and naproxen lead to stomach ulcer and bleeding. In addition, prolonged use of corticosteroids such as prednisone leads to osteoporosis. Thus, side effects associated with the anti-inflammatory drugs restrains the growth of the market.

On the other hand, strong availability and emergence of new biologic drugs for the treatment of inflammatory diseases is expected to create lucrative opportunities for the market growth. For instance, Rituximab was originally approved as a cancer drug, however it has been used for the treatment of rheumatoid arthritis since 2006.

The Asia-Pacific anti-inflammatory therapeutics market is segmented on the basis of drug class, indication, distribution channel, and country. On the basis of drug class, the market is segmented into biologics, NSAIDs, corticosteroids, and others. On the basis of indication, the market is categorized into arthritis, respiratory diseases, multiple sclerosis, psoriasis, and inflammatory bowel disease, and others.

By distribution channel, it is divided into hospital pharmacy, drug stores and retail pharmacy, and online pharmacy. Country wise, the market is analyzed across Japan, China, Australia, India, South Korea, and rest of Asia-Pacific.

On the basis of drug class, the biologics segment dominated the market in 2022, and is the fastest growing segment during the forecast period. This is attributed to strong availability of biologics drugs for the treatment of inflammatory diseases.

Depending on indication, the arthritis segment dominated the market and is expected to be the fastest growing segment during the forecast period. This is attributed to, increase in the prevalence of rheumatoid arthritis and increase in the number of people taking treatment for rheumatoid arthritis.

As per distribution channel, the drug stores and retail pharmacy segment dominated the global market in 2022 and is expected to be the fastest growing segment during the forecast period. This is attributed to, easy availability of anti-inflammatory therapeutics through drug stores and retail pharmacies.

According to Onkar Sumant, Manager, Healthcare at Allied Market Research, “The growth of Asia-Pacific anti-inflammatory therapeutics market is attributed to the increase in prevalence of inflammatory diseases, surge in R&D activities for developing novel anti-inflammatory drugs, and expansion of biologics.”

Key Findings of the Study

• By drug class, the biologics segment dominated the market in 2022.
• On the basis of indication, the arthritis segment dominated the market in 2022.
• Depending on distribution channel, the drug stores & retail pharmacies segment dominated the market in 2022.